Congenital Anomalies of the Nasolacrimal Duct

Back

Practice Essentials

The common abbreviations used for Congenital Nasolacrimal Duct Obstruction are CNLDO and for Complex Congenital Nasolacrimal Duct Obstruction C-CNLDO.  Complex means not amenable to simple treatment.[1]

Background

The congenital problems that can affect the nasolacrimal system are outlined below.

Nasolacrimal duct obstruction (NLDO) or Dacryostenosis

A very common condition in which the extreme end of the nasolacrimal duct underneath the inferior turbinate fails to complete its canalization in the newborn period and may produce clinical symptoms in 6-20% of newborns. [2]

Absence of valves

The fold that is normally present at the end of the nasolacrimal duct or the valve of Hasner may be absent, in which case pneumatoceles of the sac may occur and nose blowing may cause retrograde passage of air. If the valve of Rosenmüller also is absent, it is possible to blow air from the nose into the eye, and nosebleeds may produce bloody tears.

Anomalies of the sac

Although diverticulum of the lacrimal sac may occur, a congenital fistula of the lacrimal sac, which has been termed lacrimal anlage duct by Jones, is more common.

Anomalies of the puncta

Congenital atresia, supernumerary or double puncta, and congenital slits of the puncta all may occur. Lateral displacement of the puncta may occur in some congenital syndromes, such as blepharophimosis.

Anomalies of the canaliculi

Atresia or failure of canalization of the lacrimal canaliculi may occur in conjunction with punctal atresia.

Pathophysiology

Canalization of the nasolacrimal duct system usually is complete by the eighth month of gestation; problems in this normal developmental process can cause any of the above anomalies.[3]

The lacrimal excretory system includes the puncta, canaliculi, common canaliculi, lacrimal sac, and nasolacrimal duct, which opens at the inferior meatus over a mucosal flap called the Hasner valve.

The most common causes of congenital nasolacrimal duct obstruction are as follows:

• Membranous persistence at the distal end of the nasolacrimal duct

• Bony abnormalities with associated narrow inferior bony nasolacrimal canal

• Stenosis of the inferior meatus [4]

Epidemiology

Frequency

United States

Nasolacrimal obstruction occurs in 2-4% of newborns. Of those patients with serious nasolacrimal obstruction (nonresponsive to 2 or more probing procedures, with or without intubation), 35% have nasolacrimal duct obstruction, 15% have punctal agenesis, 10% have congenital fistulas, and 5% have craniofacial defects.

International

Nasolacrimal obstruction occurs in 2-4% of newborns.

Premature infants have a higher incidence (16%) of CNLDO.[5]

Recent studies show the incidence of nasolacrimal obstruction in children with Down syndrome is likely between 22%[6] and 36%.[7]

Mortality/Morbidity

Congenital nasolacrimal anomalies, particularly obstruction, can lead to various clinical manifestations, including the following:

Risk Factors

Infants with an elevated risk for this condition include those with trisomy 21, ectrodactyly-ectodermal dysplasia-cleft lip/palate (EEC) syndrome, branchiooculofacial syndrome, CHARGE (coloboma, heart anomaly, choanal atresia, and retardation, genital and ear anomalies) syndrome, and Goldenhar syndrome. [2]

Race

No quoted difference in racial incidence of congenital nasolacrimal system abnormalities exists.

Sex

No sexual difference exists.

Age

Nasolacrimal obstruction occurs in 2-4% of newborns.

Prognosis

Overall prognosis is excellent. More than 90% of children with these developmental anomalies have improved subjective tearing postoperatively.

History

Patient history should include the following:

Physical

A complete ophthalmic assessment must be performed. A dye disappearance test is probably the single most useful test. Place a drop of fluorescein in each eye, and monitor with a cobalt blue light; if a pool is still present after 5 minutes, the test is positive, and the baby likely has some type of obstruction in the nasolacrimal system.

Palpating the lacrimal sac may result in tears and/or mucoid discharge refluxing onto the eye through the puncta.

Measure corneal diameter, and, if suspicious, consider performing an intraocular pressure measurement. (See Glaucoma, Primary Congenital.)

Causes

Usually, these anomalies are sporadic, but genetics, prematurity, and maternal drug use can be possible influencing factors.

Ocular abnormalities are present in 20% of patients, and systemic abnormalities are present in almost 25% of patients with serious congenital nasolacrimal duct anomalies.

Complications

Neonatal dacryocystocele

Approximately 3% of infants with NLDO present in the neonatal period with a dacryocystocele. Dacryocystoceles are clinically important for two reasons. First, if the nasolacrimal duct cysts are large, they may cause respiratory problems in newborns. The second important clinical problem in these patients is the potential for acute lacrimal infection. Because infants are relatively immunocompromised in the first few months of life, these infections have the potential to spread, causing serious problems such as orbital cellulitis, meningitis, or sepsis. Prompt treatment of these infected dacryocystoceles is indicated.[8]

Imaging Studies

Imaging studies may include the following:

Other Tests

Other tests may include the following:

Histologic Findings

Punctal agenesis usually is associated with the absence of underlying canalicular tissue in 86% of cases in one series.

Medical Care

Congenital nasolacrimal duct obstructions spontaneously resolve in 90% of cases during the first year of life. Some physicians have advocated massage with digital pressure (Crigler's lacrimal sac compression) as an aid to speeding up this natural resolution.[10]  Other than massage, topical antibiotics are useful for mucopurulent discharge, but the only treatment of efficacy for those patients who do not resolve spontaneously is surgery.

Surgical Care

Probing

Probing cures 95% of congenital nasolacrimal obstructions. Prognosis for probing decreases exponentially with the increasing number of probings and the age of the patient. Rarely, it is successful after the third time or after 3 years.[11]

Nasolacrimal intubation

It has been advocated as an alternate procedure to dacryocystorhinostomy (DCR) in children who have failed probing.[12]

Success rates of 80-95% have been reported, but most patients have only been probed twice or less and are younger than 2 years. Prognosis is poor for those patients with previous dacryocystitis and for those patients in whom an obstruction is encountered during the procedure.

Lim et al noted that increasing the duration of intubation was not associated with increasing the chance of success but with a significantly higher risk for failure if longer than 18 months (P=0.03).[13] The retention of stents for longer than 12 months was associated with a significantly lower success rate (67%). The presence of Down syndrome, older age at the time of surgery, and sex of the patient were not predictive factors for treatment failure. The unplanned removal of the tubes because of dislodgement was the most common complication, occurring in 25% of eyes, but did not affect the functional outcome. Endoscopy guided probing and or intubation is a particularly effective treatment modality.[14]

Balloon catheter dilatation (dacryoplasty) of the nasolacrimal system with or without silicone tubing

This procedure has slightly better results than intubation alone. Most probing failures occur as a result of upper sac or mid duct obstructions and are not amenable to cure by instrumentation. Repeat probing procedures and intubation can cause serious complications, including false passages, canalicular scarring, and stenosis. Dacryoplasty is now being used as a primary procedure before even standard probing.[15]  The AAO did a journal review in 2018 showing its excellent results.[16]

Dacryocystorhinostomy

This treatment is the gold standard when a patent canalicular system is present.[17]  See Nasolacrimal Duct, Obstruction.

Conjunctival dacryocystorhinostomy

If the upper system is scarred or otherwise not amenable to opening, then it can be bypassed using a prosthesis, such as a Lester-Jones tube. This procedure probably should be avoided until the child is older than 10 years because the prosthesis does require care from the patient and often has minor complications and revisions. In punctal agenesis where no canalicular tissue can be identified, the insertion of a Lester-Jones tube is necessary.

Consultations

Consultations can include the following:

Complications

Bleeding: Serious bleeding is rare, occurring in only 1-2% of surgeries or postoperatively.

Surgical failures: In these complicated conditions, a 10% rate of failure occurs.

Wound infections: These occur in 5-10% of patients, usually as wound abscesses on the fourth postoperative day.

Silicone or polyethylene tubing complications: These complications occur in about 15% of cases and include the following: corneal abrasion, pyogenic granuloma, low-grade infection, chronic nasal irritation and congestion, epistaxis, sinusitis, and pharyngitis.

Bypass tube complications: These frequently occur in at least 40% of patients postoperatively and include tube loss or migration and tube obstruction.

Anesthesia complications: In children, these complications are more frequent due to drugs, blood loss, malignant hyperthermia, and pseudocholinesterase deficiency.

Long-Term Monitoring

Patients should receive follow-up care as needed.

It has been demonstrated that anisometropic amblyopia can occur in 10% to 12% of children with CLNDO. Therefore, all cases undergo a thorough ophthalmic eye examination and cycloplegic refraction, followed by careful monitoring for three to four years.[18]

Author

Donny W Suh, MD, MBA, FAAP, FACS, Professor, Department of Ophthalmology, Chief of Pediatric Ophthalmology and Adult Strabismus, Medical Director of Eye-Mobile, Gavin Herbert Eye Institute, UC Irvine Health, University of California, Irvine, School of Medicine; Associate Clinical Professor, Department of Pediatrics, Creighton University School of Medicine; Chief Medical Officer, Suh Precision Syringe, LLC; Medical Staff, Children’s Hospital of Orange County

Disclosure: Nothing to disclose.

Coauthor(s)

Christine Hakimeh, MD, Fellow in Pediatric Ophthalmology, UCI Health Gavin Herbert Eye Institute, University of California, Irvine, School of Medicine

Disclosure: Nothing to disclose.

Kourosh Shahraki, MD, Postdoctoral Research Fellow, Department of Ophthalmology, University of California, Irvine, School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Simon K Law, MD, PharmD, Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy, Sr, MD, † Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Gerhard W Cibis, MD, † Clinical Professor, Director of Pediatric Ophthalmology Service, Department of Ophthalmology, University of Kansas School of Medicine

Disclosure: Nothing to disclose.

Mounir Bashour, MD, PhD, CM, FRCSC, FACS, Assistant Professor of Ophthalmology, McGill University Faculty of Medicine; Clinical Assistant Professor of Ophthalmology, Sherbrooke University; Medical Director, Cornea Laser and Lasik MD

Disclosure: Nothing to disclose.

References

  1. Bansal O, Bothra N, Sharma A, Ali MJ. Congenital nasolacrimal duct obstruction update study (CUP study): Paper II - Profile and outcomes of complex CNLDO and masquerades. Int J Pediatr Otorhinolaryngol. 2020 Dec. 139:110407. [View Abstract]
  2. Perez Y, Patel BC, Mendez MD. Nasolacrimal Duct Obstruction. 2023 Jan. [View Abstract]
  3. Moscato EE, Kelly JP, Weiss A. Developmental anatomy of the nasolacrimal duct: implications for congenital obstruction. Ophthalmology. 2010 Dec. 117(12):2430-4. [View Abstract]
  4. Kim Y, Park JY, Lew H. Clinical Implication of Dacryoendoscopy in the Patients with Tearing: A Systematic Review. Korean J Ophthalmol. 2023 Jun. 37 (3):245-254. [View Abstract]
  5. Lorena SH, Silva JA, Scarpi MJ. Congenital nasolacrimal duct obstruction in premature children. J Pediatr Ophthalmol Strabismus. 2013 Jul-Aug. 50 (4):239-44. [View Abstract]
  6. Fimiani F, Iovine A, Carelli R, Pansini M, Sebastio G, Magli A. Incidence of ocular pathologies in Italian children with Down syndrome. Eur J Ophthalmol. 2007 Sep-Oct. 17(5):817-22. [View Abstract]
  7. Stephen E, Dickson J, Kindley AD, Scott CC, Charleton PM. Surveillance of vision and ocular disorders in children with Down syndrome. Dev Med Child Neurol. 2007 Jul. 49(7):513-5. [View Abstract]
  8. Davies R, Watkins WJ, Kotecha S, Watts P. The presentation, clinical features, complications, and treatment of congenital dacryocystocele. Eye (Lond). 2018 Mar. 32 (3):522-526. [View Abstract]
  9. Weiss AH, Baran F, Kelly J. Congenital nasolacrimal duct obstruction: delineation of anatomic abnormalities with 3-dimensional reconstruction. Arch Ophthalmol. 2012 Jul. 130(7):842-8. [View Abstract]
  10. Bansal O, Bothra N, Sharma A, Walvekar P, Ali MJ. Congenital nasolacrimal duct obstruction update study (CUP study): paper I-role and outcomes of Crigler's lacrimal sac compression. Eye (Lond). 2021 Jun. 35 (6):1600-1604. [View Abstract]
  11. Mrugacz M, Sielicka D, Bakunowicz-Lazarczyk A. [Treatment of nasolacrimal duct obstruction with probing in children younger than 4 years]. Klin Oczna. 2010. 112(7-9):221-2. [View Abstract]
  12. Komínek P, Cervenka S, Pniak T, Zeleník K, Tomášková H, Matoušek P. Monocanalicular versus bicanalicular intubation in the treatment of congenital nasolacrimal duct obstruction. Graefes Arch Clin Exp Ophthalmol. 2011 Nov. 249(11):1729-33. [View Abstract]
  13. Lim CS, Martin F, Beckenham T. Nasolacrimal duct obstruction in children: outcome of intubation. J AAPOS. 2004 Oct. 8(5):466-72. [View Abstract]
  14. Bothra N, Bansal O, Sharma A, Ali MJ. Congenital Nasolacrimal Duct Obstruction Update Study (CUP Study): Report III. Analysis of Earlier Failed Probing without Endoscopy Guidance. Semin Ophthalmol. 2022 Feb 17. 37 (2):249-252. [View Abstract]
  15. Gazit I, Pras E, Or L, Hartstein ME. Balloon catheter dilation as the primary treatment of congenital nasolacrimal duct obstruction. Eur J Ophthalmol. 2021 Mar. 31 (2):334-339. [View Abstract]
  16. Wladis EJ, Aakalu VK, Yen MT, Bilyk JR, Sobel RK, Mawn LA. Balloon Dacryoplasty for Congenital Nasolacrimal Duct Obstruction: A Report by the American Academy of Ophthalmology. Ophthalmology. 2018 Oct. 125 (10):1654-1657. [View Abstract]
  17. Rajabi MT, Shahraki K, Nozare A, Moravej Z, Tavakolizadeh S, Salim RE, et al. External versus Endoscopic Dacryocystorhinostomy for Primary Acquired Nasolacrimal Duct Obstruction. Middle East Afr J Ophthalmol. 2022 Jan-Mar. 29 (1):1-6. [View Abstract]
  18. Yoo Y, Yang HK, Kim N, Choung HK, Hwang JM, Khwarg SI. Amblyopia risk factors in congenital nasolacrimal duct obstruction: A longitudinal case-control study. PLoS One. 2019. 14 (6):e0217802. [View Abstract]
  19. Bowling BS, Chandna A. Superior lacrimal canalicular atresia and nasolacrimal duct obstruction in the CHARGE association. J Pediatr Ophthalmol Strabismus. 1994 Sep-Oct. 31(5):336-7. [View Abstract]
  20. Busse H. [Connatal dacryostenoses. Clinical picture and treatment]. Ophthalmologe. 2004 Sep. 101(9):945-54; quiz 955-6. [View Abstract]
  21. Cahill KV, Burns JA. Management of epiphora in the presence of congenital punctal and canalicular atresia. Ophthal Plast Reconstr Surg. 1991. 7(3):167-72. [View Abstract]
  22. Chronister CL, Lee A, Kaiser H. Rarely reported cases of congenital atresia of nasolacrimal puncta. Optometry. 2002 Apr. 73(4):237-42. [View Abstract]
  23. Foster JA, Katowitz JA, Heyman S. Results of dacryoscintigraphy in massage of the congenitally blocked nasolacrimal duct. Ophthal Plast Reconstr Surg. 1996 Mar. 12(1):32-7. [View Abstract]
  24. Holzberg N, Ward RF. Bilateral congenital dacrocystoceles. Otolaryngol Head Neck Surg. 1993 Dec. 109(6):1074-7. [View Abstract]
  25. Ingels K, Kestelyn P, Meire F, Ingels G, Van Weissenbruch R. The endoscopic approach for congenital nasolacrimal duct obstruction. Clin Otolaryngol Allied Sci. 1997 Apr. 22(2):96-9. [View Abstract]
  26. Lyon DB, Dortzbach RK, Lemke BN, Gonnering RS. Canalicular stenosis following probing for congenital nasolacrimal duct obstruction. Ophthalmic Surg. 1991 Apr. 22(4):228-32. [View Abstract]
  27. Lyons CJ, Rosser PM, Welham RA. The management of punctal agenesis. Ophthalmology. 1993 Dec. 100(12):1851-5. [View Abstract]
  28. McNab AA. Congenital absence of the nasolacrimal duct. J Pediatr Ophthalmol Strabismus. 1998 Sep-Oct. 35(5):294-5. [View Abstract]
  29. Paul TO, Shepherd R. Congenital nasolacrimal duct obstruction: natural history and the timing of optimal intervention. J Pediatr Ophthalmol Strabismus. 1994 Nov-Dec. 31(6):362-7. [View Abstract]
  30. Sevel D. Development and congenital abnormalities of the nasolacrimal apparatus. J Pediatr Ophthalmol Strabismus. 1981 Sep-Oct. 18(5):13-9. [View Abstract]
  31. Ugurbas SH, Zilelioglu G. Congenital lacrimal fistula. Eur J Ophthalmol. 2000 Jan-Mar. 10(1):22-6. [View Abstract]
  32. Welham RA, Hughes SM. Lacrimal surgery in children. Am J Ophthalmol. 1985 Jan 15. 99(1):27-34. [View Abstract]